Actinic Keratosis

Actinic keratosis remains a public health problem for older adults, occurring in approximately three of every 10 Medicare recipients, according to a research letter published in JAMA Dermatology.

Noninvasive diagnostic methods such as dermoscopy and confocal reflectance microscopy may have utility in minimizing biopsy use in predicting progression of actinic keratosis to carcinoma, according to a study.

WAILEA, Hawaii — In this video perspective from Maui Derm for Dermatologists, George Martin, MD, the meeting’s program director, gives an update on cutaneous oncology treatment options that were discussed during the meeting’s first day.

Combination therapy with photodynamic treatment and aminolevulinic acid 20% solution has shown strong outcomes with minimal adverse events in actinic keratoses, according to results of a meta-analysis.

Klisyri is available for prescription in Germany and the U.K., according to a press release from Almirall.

Photodynamic therapy with aminolevulinate and imiquimod are among the treatments with good long-term efficacy for actinic keratosis, according to an investigation published in JAMA Dermatology.

Klisyri has received a positive opinion for the treatment of actinic keratosis from the European Medicines Agency’s Committee for Medicinal Products for Human Use, Almirall announced in a press release.

Diagnosis with actinic keratosis at age younger than 49 years or older than 80 years was associated with elevated cutaneous squamous cell carcinoma risk, according to a study.

Klisyri, a topical treatment for actinic keratosis, has been launched by Almirall following a December approval by the FDA, according to a press release.

Klisyri, an FDA-approved Src kinase signaling inhibitor, was superior to placebo for the treatment of actinic keratoses, according to findings from two double-blind randomized trials published in The New England Journal of Medicine.